Toxicology and Safety Studies are Successfully Completed

Redwood Pharma AB (publ) announces that the RP101 toxicology studies are now successfully completed. The Company can thereby continue the development of RP101 and approach the next goal of starting the clinical Phase II study in patients with chronic dry eye disease.

Safety studies are a critical step in the development of a pharmaceutical. Redwood Pharma has now successfully completed these regarding RP101, which is a new candidate drug based on a well-known active substance and IntelliGel® - that will for the first time be used in an ophthalmological treatment, which will be administered directly onto the front of the eye. The completion of the studies confirms that RP101 and the IntelliGel platform do not result in any significant toxicology effects. This means for the development of RP101 and the IntelliGel platform that Redwood Pharma can:

-       Seek an advisory meeting with the (Swedish) Medical Products Agency to finalize our working development plan.

-       Finalize regulatory documentation needed for the clinical trial application.

-       Intensify activities to find a new area of use (new products) that could benefit from IntelliGel.

CEO Martin Vidaeus is quite positive to the developments, ”These safety data contribute to RP101s strength as a future therapy to treat dry eye disease and increases the opportunity for the use of IntelliGel together with other active substances. With these results in hand, we continue to be optimistic about the Company’s future commercial potential. The positive results minimize development and investment risks – at the same time the value of Redwood Pharma increases.”

For more information:
Martin Vidaeus, CEO Redwood Pharma AB (publ.)
Tel: +46 (0) 70 232 29 29
E-mail: martin.vidaeus@redwoodpharma.com

This information is information that Redwood Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, November 20, 2017.

About Redwood Pharma AB
Redwood Pharma develops ophthalmic products for unmet medical needs. The Company’s first project is the development of drug candidate RP101 with a known active substance against chronic dry eye in postmenopausal women who have moderate to severe symptoms. With the drug delivery platform IntelliGel® the release of active substances is controlled. Through the use of IntelliGel, Redwood Pharma can also improve dosing of other established drugs. Redwood Pharma’s strength lies in formulation and early clinical development. Revenues will be generated through licensing agreements with pharmaceutical companies that have capabilities to manufacture and sell commercial products worldwide.

Redwood Pharma AB (publ.) is listed on AktieTorget, a Swedish Multilateral Trading Facility (Ticker: REDW.ST, ISIN: SE008294789).
For more information visit: www.redwoodpharma.com